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A remarkable development in the post-
genome era is the emergence of proteomics as
a new discipline that is rooted in old fashioned
chemistry and biochemistry, as well as molec-
ular biology and genomics. Chemistry has pro-
vided basic strategies for sorting proteins into
classes with different properties and for eluci-
dating their posttranslational modifications,
and biochemistry has contributed decades of
know-how in elucidating functional aspects of
proteins and their involvement in different
pathways. Genomics has provided a sequence-
based framework for mining proteomics data.
Molecular biology has contributed numerous
tools for manipulating proteins and for eluci-
dating their interactions and their occurrence
as part of complexes. 
What about clinical proteomics? The past
few years have seen a tremendous interest in
the potential ability of proteomics to address
many unfulfilled needs in clinical research.
Such unmet needs include more effective
strategies for early disease detection and
monitoring, more effective therapies, and
developing a better understanding of disease
pathogenesis. Proteomics is particularly suited
for investigating biological fluids to identify
disease related alterations and to develop
molecular signatures for disease processes. A
mobilization effort is under way involving
academia, governments, industry, and philan-
thropy to develop agendas for medical pro-
teomics. This is reflected for example in the
prominence of proteomics in the National
Institues of Health (NIH) roadmap, in the
interest on the part of major medical centers
to develop plans for faculty recruitment, for
investing in proteomics resources, and for
developing a focus on specific diseases based
on areas of strengths at their institutions. It is
also reflected in the prominence given to pro-
teomics at annual meetings of societies that
have a disease focus, from heart disease to
cancer.
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With heightened expectations that pro-
teomics will deliver and overcome some of the
limitations of other approaches, or at least
complement them, it is important to keep in
mind that a solid foundation for the field
first needs to be developed Such a foundation
includes the development of adequate resources
and technologies as well as training and edu-
cation programs. There is also a need for vehi-
cles for information dissemination, as Clinical
Proteomics intends to provide, and judging
from the contents of this first issue, it is evi-
dent that the scope of Clinical Proteomics is
well suited for the field.
What kind of resources and technologic
innovations are needed in clinical proteomics?
Proteomics involves the analysis of the global
proteome of a cell, a tissue, or a biological
fluid. An added requirement for clinical pro-
teomics is the need to analyze large numbers
of samples, given the substantial variability
one encounters with disease samples. The
variability results not only from heterogeneity
that characterizes disease states but also from
numerous others sources such as the sample
procurement process itself. Consequently, there
is a need for high-throughput to analyze sam-
ples in sufficient numbers to reach statistical
significance. A further challenge is to figure
out how to develop proteome-scale quantita-
tive read-outs to fulfill expectations of advanc-
ing our understanding of basic biology and of
disease processes. There is currently no single
technology that allows such analyses and
much effort is intended to further develop
proteomics technologies to expand their reach.
Nevertheless, even with the limited scope of
current proteomics technologies, numerous
disease related investigations may be envis-
aged. For example, subproteomes are more
amenable to comprehensive profiling than the
whole proteome and investigations of alter-
ations involving specific cell compartments or
specific subsets of proteins are quite feasible.
Also, classifying disease based on proteomic
profiling does not necessitate analysis of all
protein constituents. Identifying novel protein
targets for therapy is also feasible with current
technologies. It should, however, be empha-
sized that no matter how limited the current
technologies might be, expediency is not a
substitute for rigor in scientific inquiry, from
experimental design to data interpretation to
validation, the latter being particularly crucial
to determine clinical relevance.
Besides technology development, there is a
need for developing resources to facilitate the
application of proteomics to disease investiga-
tions. A case in point, the Human Proteome
Organization (HUPO.org) is engaged in an
effort to develop such resources. There is a
substantial need for informatics resources in
proteomics for practically every aspect of
the field. For example, the current approaches
to the analysis of protein data are highly
informal and nonstandardized. An important
informatics related effort that HUPO is
involved in is aimed at developing and adopt-
ing standardized approaches that facilitate the
cross-lab analysis of proteomics data through
a Proteomics Standards Initiative (PSI). HUPO
hopes that publishers will adopt recommen-
dations resulting from this initiative. The
initial focus has been on protein–protein
interaction data and mass spectrometry data.
HUPO PSI has proposed a community stan-
dard data model for the representation and
exchange of protein interaction data. This data
model is supported by major protein interac-
tion data providers. Progress has also been
made in the development of common stan-
dards for data exchange in the field of mass
spectrometry. HUPO informatics efforts will
also extend to other aspects of proteomics
such as quantitative protein expression analy-
sis. They will also address the needs of
HUPO’s targeted tissue and disease prote-
omics initiatives with respect to data collec-
tion, storage, and dissemination, which will be
broadly relevant to clinical proteomics.
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Another major resource related initiative is
the development of genome scale protein cap-
ture agents. The plans under development
consist of initially making antibodies for the
proteins identified as part of the HUPO pro-
teome projects and eventually making anti-
bodies to all the proteins encoded in the
human genome. These antibodies will allow
proteome scale studies to be done as in the
case of antibody microarrays that assay pro-
teins in a tissue or biological fluid. 
An issue that has become quite important
in this era of genome and proteome scale
investigations is data sharing. The capacity
to generate data far exceeds the ability of
one group to fully mine such data. Further-
more, it is advantageous for data mining
to have access to multiple sets of data. It is
therefore crucial that published data is acces-
sible to other investigators. In this respect,
investigators, funding agencies, and publish-
ers share a responsibility to facilitate access to
data.
Clinical Proteomics will undoubtedly chroni-
cle the progress made in this growing field
through its articles and special features.
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